20,000 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Bought by Maven Securities LTD

Maven Securities LTD bought a new position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $1,391,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. CWM LLC grew its position in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares in the last quarter. HighTower Advisors LLC lifted its stake in Structure Therapeutics by 3.6% in the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after purchasing an additional 320 shares during the last quarter. State of Wyoming lifted its stake in Structure Therapeutics by 29.7% in the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after purchasing an additional 403 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Structure Therapeutics by 9.4% in the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after purchasing an additional 413 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Structure Therapeutics by 4.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after purchasing an additional 444 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on GPCR. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Canaccord Genuity Group began coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 price target for the company. Finally, Wolfe Research began coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $42.93 on Monday. The company has a market cap of $3.05 billion, a price-to-earnings ratio of -49.34 and a beta of -1.35. The company has a 50-day moving average price of $43.64 and a 200-day moving average price of $57.33. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $15.80 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. As a group, research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.